title: Down-Regulated Phosphoglycerate Kinase 1 Expression Is Associated With Poor Prognosis in Patients With Gallbladder Cancer.
abstract: To evaluate prognostic significance of phosphoglycerate kinase 1 (PGK1) protein expression in patients with gallbladder cancer (GBC).Ninety-five patients who underwent surgical resection for GBC between January 2004 and December 2010 were enrolled. Overall survival (OS) and disease-free survival (DFS) were evaluated over a 10-year follow-up. PGK1 expression was assessed by tissue microarray and immunohistochemistry. Prognostic significance was analyzed using multivariate Cox regression.PGK1 was highly expressed in all gallbladder mucosa. Decreased PGK1 expression was detected in 54.7% (52/95) of patients with GBC. It was significantly down-regulated in GBC samples compared with that in gallbladder mucosa (P < 0.0001), and was associated with multiple clinicopathological factors. Multivariate survival analysis showed that low PGK1 expression was associated with shorter OS (median 12.8 vs 45.4 months; hazard ratio [HR] = 3.077; 95% confidence interval [CI], 1.373-6.897; P = 0.006) and DFS (median 8.3 vs 37.9 months; HR = 2.988; 95% CI, 1.315-6.790; P = 0.009), indicating that PGK1 expression was an independent prognostic factor in patients with GBC.Low PGK1 expression was associated with progression in patients with GBC. PGK1 expression could be a useful prognostic biomarker for GBC.
authors.affiliation: From the General Surgery Department and Research Institute, Xinhua Hospital, Affiliated with School of Medicine, Shanghai Jiao Tong University, Shanghai, China (WL, YC, ML, YL); Center of Clinical Epidemiology and Evidence-Based Medicine, Fudan University, Shanghai, China (JG); Institute of Biliary Tract Diseases Research, School of Medicine (WL, YC, LJ, ML, YZ, JZ, YL) and Institute of Social Cognitive and Behavioral Sciences (WL), Shanghai Jiao Tong University, Shanghai, China; and Rush Alzheimer's Disease Center (JY) and Department of Neurological Sciences (JY), Rush University Medical Center, Chicago, IL.
authors.forename: Wei
authors.initials: W
authors.lastname: Lu
authors.forename: Jian
authors.initials: J
authors.lastname: Gao
authors.forename: Jingyun
authors.initials: J
authors.lastname: Yang
authors.forename: Yang
authors.initials: Y
authors.lastname: Cao
authors.forename: Lin
authors.initials: L
authors.lastname: Jiang
authors.forename: Maolan
authors.initials: M
authors.lastname: Li
authors.forename: Yijian
authors.initials: Y
authors.lastname: Zhang
authors.forename: Jian
authors.initials: J
authors.lastname: Zhou
authors.forename: Yingbin
authors.initials: Y
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor; D018572:Disease-Free Survival; D015536:Down-Regulation; D005260:Female; D005704:Gallbladder / Q000378:metabolism; D005706:Gallbladder Neoplasms / Q000378:metabolism* / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010735:Phosphoglycerate Kinase / Q000096:biosynthesis*; D011379:Prognosis; D012372:ROC Curve
chemical_list: D014408:Biomarkers, Tumor; D010735:Phosphoglycerate Kinase